公开(公告)号：US20190060869A1

公开(公告)日：2019-02-28

申请号：US16189894

申请日：2018-11-13

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Martin Hall ,  Sture Larsson ,  Andreas Muranyi ,  Gustav Rodrigo ,  Jinyu Zou ,  Per-Mikael Aberg

IPC: B01J20/24 ,  B01D15/38 ,  C07K16/00 ,  B01J20/32 ,  C07K17/10 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  C07K14/31 ,  C07K1/22 ,  B01J20/286 ,  C07K17/00

CPC classification number: B01J20/24 ,  B01D15/3809 ,  B01J20/28019 ,  B01J20/285 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  B01J20/3293 ,  B01J2220/52 ,  B01J2220/54 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  C07K17/10 ,  C07K2317/55

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

公开(公告)号：US10213765B2

公开(公告)日：2019-02-26

申请号：US15603285

申请日：2017-05-23

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Martin Hall ,  Sture Larsson ,  Andreas Muranyi ,  Gustav Rodrigo ,  Jinyu Zou ,  Per-Mikael Aberg

IPC: C07K1/22 ,  B01D15/38 ,  B01J20/24 ,  B01J20/286 ,  B01J20/32 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  C07K17/10

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

公开(公告)号：US10189891B2

公开(公告)日：2019-01-29

申请号：US14385336

申请日：2013-03-26

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Mats Ander ,  Goran Bauren ,  Tomas Bjorkman ,  Per-Mikael Aberg ,  Gustav Rodrigo

IPC: C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  B01J20/286 ,  B01D15/38 ,  B01J20/291 ,  G01N33/68 ,  B01J20/32

Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.

公开(公告)号：US20170259244A1

公开(公告)日：2017-09-14

申请号：US15603285

申请日：2017-05-23

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Martin Hall ,  Sture Larsson ,  Andreas Muranyi ,  Gustav Rodrigo ,  Jinyu Zou ,  Per-Mikael Aberg

IPC: B01J20/24 ,  C07K14/31 ,  C07K17/10 ,  B01D15/38 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  B01J20/32 ,  C07K1/22 ,  C07K16/00

CPC classification number: B01J20/24 ,  B01D15/3809 ,  B01J20/28019 ,  B01J20/285 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  B01J20/3293 ,  B01J2220/52 ,  B01J2220/54 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  C07K17/10 ,  C07K2317/55

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

公开(公告)号：US20190023735A1

公开(公告)日：2019-01-24

申请号：US16115756

申请日：2018-08-29

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jean-Luc Maloisel ,  Gustav Rodrigo ,  Bjorn Noren ,  Virendra Kumbhar

IPC: C07K1/16 ,  B01J20/32 ,  C07K1/36 ,  B01J20/28 ,  B01J20/26 ,  B01D15/38 ,  G01N33/544 ,  B01J20/289 ,  B01J41/20 ,  B01D15/36 ,  B01D15/32

Abstract: The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five-or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.

公开(公告)号：US10124328B2

公开(公告)日：2018-11-13

申请号：US15407240

申请日：2017-01-16

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jesper Hansson ,  Gustav Rodrigo ,  Tobias E Soderman

IPC: B01J39/26 ,  B01D15/18 ,  B01D15/36 ,  B01J20/286 ,  B01J20/32 ,  B01D15/38 ,  B01J20/26 ,  B01J20/28 ,  B01J20/289 ,  B01J20/30 ,  C07H1/08 ,  C07K1/22 ,  B01D15/34 ,  B01J20/24 ,  G01N30/88

Abstract: The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH2═CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.

公开(公告)号：US20180244729A1

公开(公告)日：2018-08-30

申请号：US15900419

申请日：2018-02-20

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Gustav Rodrigo ,  Mats Ander ,  Tomas BJORKMAN ,  Goran Bauren

IPC: C07K14/31 ,  B01D15/38 ,  C07K14/745 ,  C07K1/22 ,  C07K16/00 ,  B01J20/32 ,  B01J20/286

CPC classification number: C07K14/31 ,  B01D15/3809 ,  B01J20/286 ,  B01J20/3204 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  C07K1/22 ,  C07K14/745 ,  C07K16/00

Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.

公开(公告)号：US20180044374A1

公开(公告)日：2018-02-15

申请号：US15798784

申请日：2017-10-31

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Annika Forss ,  Mats Ander ,  Tomas Bjorkman ,  Hans Blom ,  Jesper Hansson ,  Gustav Rodrigo

IPC: C07K1/16 ,  B01D15/18 ,  B01J20/285 ,  B01D15/34 ,  C07K16/00 ,  B01J20/286

CPC classification number: C07K1/165 ,  B01D15/1807 ,  B01D15/1864 ,  B01D15/34 ,  B01J20/285 ,  B01J20/286 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2319/30

Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.

公开(公告)号：US09663559B2

公开(公告)日：2017-05-30

申请号：US15063471

申请日：2016-03-07

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Martin Hall ,  Sture Larsson ,  Andreas Muranyi ,  Gustav Rodrigo ,  Jinyu Zou ,  Per-Mikael Aberg

IPC: C07K14/31 ,  B01D15/38 ,  B01J20/286 ,  C07K1/22 ,  B01J20/32 ,  C07K16/00 ,  C07K17/00

CPC classification number: B01J20/24 ,  B01D15/3809 ,  B01J20/28019 ,  B01J20/285 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  B01J20/3293 ,  B01J2220/52 ,  B01J2220/54 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  C07K17/10 ,  C07K2317/55

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

公开(公告)号：US09573973B2

公开(公告)日：2017-02-21

申请号：US14396207

申请日：2013-04-22

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Jesper Hansson ,  Gustav Rodrigo ,  Tobias E Soderman

IPC: B01D15/36 ,  C07K1/22 ,  B01D15/18 ,  B01J20/286 ,  B01J20/32 ,  B01D15/38 ,  B01J20/26 ,  B01J20/28 ,  B01J20/289 ,  B01J20/30 ,  C07H1/08 ,  G01N30/88

CPC classification number: B01J39/26 ,  B01D15/1864 ,  B01D15/34 ,  B01D15/361 ,  B01D15/362 ,  B01D15/3809 ,  B01J20/24 ,  B01J20/261 ,  B01J20/265 ,  B01J20/267 ,  B01J20/28014 ,  B01J20/28033 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3085 ,  B01J20/3212 ,  B01J20/3278 ,  B01J20/3282 ,  B01J2220/80 ,  C07H1/08 ,  C07K1/22 ,  G01N2030/8827 ,  Y02P20/582

Abstract: The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH2═CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.

Abstract translation: 本发明公开了一种从液体中的至少一种其它组分分离生物分子的方法，包括使所述液体与包含固体支持物和与所述固体支持物结合的聚合物链的分离基质接触的步骤。 聚合物链包含衍生自结构为CH 2 = CH-L-X的第一单体的单元，其中L为共价键或包含2-6个碳原子的烷基醚或羟基取代的烷基醚链，X为磺酸盐或膦酸酯基团。